Neuraxis (NRXS) Stock: Buy, Sell, or Hold?
NRXS - Neuraxis, Inc.
$7.11
-0.06 (-0.84%)
âŧ
5d:
-5.95%
30d:
+19.5%
90d:
-0.7%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When NRXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NRXS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NRXS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NRXS is currently trading at $7.11, which is considered slightly high relative to its 30-day fair value range of $5.81 to $7.36.
Technical Outlook: Technically, NRXS is in a downtrend. The price is currently testing key support at $6.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+54.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRXS is in a downtrend. The price is currently testing key support at $6.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+54.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.81 -
$7.36
Company Quality Score
33/100
(SELL)
Options IV Signal
42th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
47.9%
All Signals
- NEUTRAL: Options fairly priced (IV 42th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.7% below Wall St target ($11.00)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.81 -
$7.36
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.90
(12.6%)
Support & Resistance Levels
Support Level
$6.94
Resistance Level
$8.05
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.33
Wall Street Target
$11.00
(+54.7%)
Revenue Growth (YoY)
115.7%
Profit Margin
-144.4%
Share & Embed Analysis
Last updated: October 03, 2026 6:14 PM ET
Data refreshes hourly during market hours. Next update: 7:14 PM
Data refreshes hourly during market hours. Next update: 7:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 55 HOLD |
